Global Hemophilia Market Report: 2013 Edition- Koncept Analytics

661 views

Published on

Hemophilia is a disorder in which the blood does not clot properly, leading to extended bleeding. The bleeding can be external or internal, especially in the knees, ankles, and elbows. There are two types of hemophilia: type A and type B. The market has been growing since past several years mainly due to improvement in technology, discovery of new coagulation factors, proteins, and plasma concentrates which are being used for treating chronic diseases and medical conditions.
As more people suffer with Hemophilia A in comparison with Hemophilia B and Inhibitors, the Hemophilia A market is the largest in the world. The US accounts for the major population suffering with hemophilia globally.
The key trends observed within the market include inclination towards prophylaxis, long-acting factor VIII and IX development and growing penetration of rFVIII products in emerging markets which is a opportunity for manufacturers. On the development front, there has been an increase in the launch of new products by various companies. But there are certain challenges which the industry is facing as of now which include risk of antibody neutralization, emerging challenges for developing nations and rising cost of hemophilia treatment. The major factors which will contribute in the growth of the industry include rising male population, increasing expenditure on healthcare and increasing new patient registration.
The report studies the hemophilia market on a global scale and its various segments. The competition in the global hemophilia market is intense with few large players viz. Baxter, Grifols, Pfizer and Nova Noridisk. The competitive landscape along with the company profiles of the leading players in the market is discussed in detail.

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
661
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Global Hemophilia Market Report: 2013 Edition- Koncept Analytics

  1. 1. Global Hemophilia Market -------------------------------------------- 2013 View Report Details
  2. 2. Executive Summary Hemophilia is a disorder in which the blood does not clot properly, leading to extended bleeding. The bleeding can be external or internal, specially in the knees, ankles, and elbows. There are two types of hemophilia: type A and type B. The market has been growing since past several years mainly due to improvement in technology, discovery of new coagulation factors, proteins, and plasma concentrates which are being used for treating chronic diseases and medical conditions. As more people suffer with Hemophilia A in comparison with Hemophilia B and Inhibitors, the Hemophilia A market is the largest in the world. The US accounts for the major population suffering with hemophilia globally. The key trends observed within the market include inclination towards prophylaxis, long-acting factor VIII and IX development and growing penetration of rFVIII products in emerging markets which is a opportunity for manufacturers. On the development front, there has been an increase in the launch of new products by various companies. But there are certain challenges which the industry is facing as of now which include risk of antibody neutralization, emerging challenges for developing nations and rising cost of hemophilia treatment. The major factors which will contribute in the growth of the industry include rising male population, increasing expenditure on healthcare and increasing new patient registration. The report studies the hemophilia market on a global scale and its various segments. The competition in the global hemophilia market is intense with few large players viz. Baxter, Grifols, Pfizer and Nova Noridisk. The competitive landscape along with the company profiles of the leading players in the market is discussed in detail. By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests. View Report Details
  3. 3. Hemophilia is linked to recessive X genes, which leads to the inability to synthesize clotting factor…..  The number of patients treated with hemophilia increased from …… in 2010 to ……. in 2011 showing a growth of …..%. In 2012, the numbers of patients treated with hemophilia were estimated to have increased to ……. showing a rise of …….% in comparison with 2011. The global hemophilia treatment market revenues showed a growth of …..% rising from US$....... billion in 2010 to US$....... billion in 2011. In 2012, the market was estimated to have reached US$........ billion showing an increase of …..% in comparison with 2011. Industry Developments : -Baxter Announced ADVATE Approval in China for the Treatment of Hemophilia A - Baxter Expands Access to Recombinant FVIII Hemophilia Treatment in Brazil - Novo Nordisk Files New Hemophilia Drug in EU, US Industry Key Trends : -Shift towards Prophylaxis - Long-Acting Factor VIII and IX Development - Rising Penetration of rFVIII Products in Emerging Markets Market Growth Drivers - Rising Male Population - Increasing Expenditure on Healthcare -Increasing New Patient Registration Challenges -Risk of Antibody Neutralization - Emerging Challenges for Developing Nations -Rising Cost of Hemophilia Treatment Number of Treated Patients with Hemophilia (2010-2012E) Global Hemophilia Treatment Market Revenues (2008-2012E) 2010 2011 2012E 2008 2009 2010 2011 2012E US$Billion
  4. 4. Globally, patients suffering from Hemophilia A was more than Hemophilia B and patients with identifier…… In 2011, the numbers of patients treated with hemophilia A were …… showing an increase of ……. % from …….. patients in 2010. The numbers of patients treated with hemophilia A were estimated to be …….. in 2012 showing a growth of …….%. The number of patients treated with Hemophilia B increased from ……. in 2010 to ……. in 2011 showing a rise of ……%. The same was estimated to have increased by ……% in 2012 in comparison with 2011.  There were ……. patients globally with inhibitors in 2011 which increased by ……% in comparison with 2010, and the vast majority were hemophilia A patients. In 2012, the numbers of patients with inhibitors were estimated to be ……. showing a growth of ……% as compared to 2011. Number of Treated Patients with Hemophilia B (2010-2012E) Number of Treated Patients with Hemophilia A (2010-2012E) 2010 2011 2012E 2010 2011 2012E Number of Patients Identified with Inhibitor (2010-2012E) 2010 2011 2012E
  5. 5. The Global Hemophilia Market is highly fragmented and companies face intense competition. In 2011, the market leader was Baxter. The number of people treated with hemophilia in the United States was ….. in 2010 which increased to …… in 2011 showing a rise of ……%. The same was estimated to rise to …….. in 2012 witnessing a growth of …..% in comparison with 2011. On the competition front, Baxter was the leading company in the hemophilia market world over, with approximately ……% of the market share for the year 2011, followed by Novo Nordisk and Pfizer with ……% and ….. % respectively.  The global hemophilia market increased from US$...... billion in 2011 to US$...... billion in 2012 showing an increase of …..%. The market is forecasted to reach US$..... billion in 2013 showing a rise of ……%. The global hemophilia treatment market is expected to grow at a CAGR of …..% for the period spanning 2011-2016. Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa 2011 2012 2013F 2014F 2015F 2016F US$Billion Global Hemophilia Treatment Market Forecast (2011-2016F) 2010 2011 2012E No. of Hemophilia Patients Treated in the US (2010-2012E)
  6. 6. Table of Contents 1. Hemophilia: An Overview -Sign & Symptoms -Types of Hemophilia -Treatment 2. Market Overview 2.1 Global Hemophilia Market -Market Value -Patient Volume 2.2 Hemophilia Market by Segments 2.2.1 Hemophilia A -Market Value -Patient Volume -Key Products Comparison -FVIII Market 2.2.2 Hemophilia B -Market Value -Patient Volume -Key Products Comparison -FIX Market List of Graphs & Tables List of Charts Types of Hemophilia Worldwide Patients Treated with Hemophilia (2010-2012E) Global Hemophilia Treatment Market Revenues (2008-2013E) Worldwide Patients Treated with Hemophilia A (2010-2012E) Global Hemophilia A Market Size (2010-2012E) Global Recombinant FVIII Market Revenues (2005-2012E) Worldwide Patients Treated with Hemophilia B (2010-2012E) Global Hemophilia B Market Size (2010-2012E) Global Recombinant FIX Market Size (2006-2012E) Global Recombinant FIX Consumption (2005-2011) Global Recombinant FIX Consumption Market Share (2011) Worldwide Patients Treated with Inhibitor (2010-2012E) Global Inhibitor Market Size (2010-2013E) Demand of Plasma Derived Factor IX in Australia (2008-2012) Demand of Recombinant Factor IX in Australia (2008-2012) Number of Hemophilia Patients Treated in the US (2010-2012E) The US Hemophilia Market Value (2010-2012E) Global Male Population (2005-2014F) Healthcare Expenditure Worldwide (2005-2012E) New Patient Registrations in Global Bleeding Disorders Market (2008- 2012) Global Hemophilia Market Share (2011) Global Recombinant Coagulation (FVII, FVIII, FIX) Market (2011)
  7. 7. 2.2.3 Hemophilia with Inhibitor -Market Value -Patient Volume -Key Products 2.2.4 Von Willebrand Disease 2.3 Hemophilia Market by Region 2.3.1 Australia 2.3.2 The US -Market Value -Patient Volume -Market Segments -FVIII Market -FIX Market 3. Market Dynamics 3.1 Key Trends 3.1.1 Shift towards Prophylaxis 3.1.2 Long-Acting Factor VIII and IX Development 3.1.3 Rising Penetration of rFVIII Products in Emerging Markets 3.2 Growth Drivers Global Recombinant FVIII Market Share (2012E) Baxter’s Revenue by Business Segments (2012) Baxter’s Revenues and Net Income (2008-2012) Grifols Revenue Share by Business Segments (2012) Grifols Revenue Share by Geographical Segments (2012) Grifols’ Revenues & Net Profit (2008-2012) Novo Nordisk’s Revenue Share by Business Segments (2012) Novo Nordisk’s Revenue Share by Region (2012) Sales and Net Income of Novo-Nordisk (2008-2012) Pfizer’s Revenue Share by Business Segments (2012) Pfizer’s Revenue Share by Geographical Segments (2012) Pfizer’s Revenues & Net Income (2008-2012) Global Hemophilia Treatment Market Forecast (2011-2016F) Tables Revenues of Key Products in Hemophilia A Treatment Market (2011- 2016F) Products for Hemophilia A Treatment Products for Treatment of Hemophilia B Inhibitor Treatment (2010-2012E) US Hemophilia Market by Segments (2010-2012E) Volume of FVIII Market in the US (2008-2012) US FIX Consumption (2005-2011) US Factor (M IU) Consumption by Treatment Type and Patient Age (2012-2020) Hemophilia A patients by Treatment Category (2012) Long Acting FIX & FVIII in Early and Late-Stage Development
  8. 8. 3.2.1 Rising Male Population 3.2.2 Increasing Expenditure on Healthcare 3.2.3 Increasing New Patient Registration 3.3 Significant Developments 3.3.1 Baxter Announced ADVATE Approval in China 3.3.2 Baxter Expands Access to Recombinant FVIII Hemophilia Treatment in Brazil 3.3.3 Novo Nordisk Files New Hemophilia Drug in EU, US 3.4 Challenges 3.4.1 Risk of Antibody Neutralization 3.4.2 Emerging Challenges for Developing Nations 3.4.3 Rising Cost of Hemophilia Treatment 4. Competitive Scenario -Market Share -Product Comparison 5. Company Profiles 5.1 Baxter International Inc. % Conversion to Recombinant Factor VIII Products in Selected Countries (2011) Competition in Hemophilia A Market – Emerging Products Competition in Hemophilia B Market – Emerging Products Competition in Inhibitor Market – Emerging Products Competition in von Willebrand Market – Emerging Products Dependent & Independent Variables (2008-2012) Correlation Matrix Model Summary – Coefficient of Determination Regression Coefficients Output
  9. 9. 5.1.1 Business Overview 5.1.2 Financial Overview 5.1.3 Business Strategies -Advancement of Core Portfolio -Expansion of Product Portfolio 5.2 Grifols 5.2.1 Business Overview 5.2.2 Financial Overview 5.2.3 Business Strategies -Expansion in Other Geographic Regions -Growth through Mergers & Acquisitions 5.3 Novo Nordisk 5.3.1 Business Description 5.3.2 Financial Highlights 5.3.3 Business Strategies -Product Innovation 5.4 Pfizer, Inc. 5.4.1 Business Overview 5.4.2 Financial Highlights 5.4.3 Business Strategies -Expansion in Emerging Markets -Growth through Acquisitions
  10. 10. 6. Market Outlook 6.1 Market Forecast 6.2 Forecast Methodology 6.2.1 Dependent and Independent Variables 6.2.2 Correlation Analysis 6.2.3 Regression Analysis
  11. 11. Koncept Analytics CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T. +91-120-4130959 C: +91-9811715635 vikas@konceptanalytics.com Contact Us: www.konceptanalytics.com Vikas Gupta BD Manager These are abridged and sanitized sample pages from the comprehensive report on the “Global Hemophilia Market”. To know more about this report or for any customized research requirement, please contact the following: View Report Details

×